Tumor markers in the diagnosis of cancer of the corpus uteri (a review of literature)
https://doi.org/10.17650/1994-4098-2013-0-3-4-67-71
Abstract
Towards the end of the past century, cancer of the corpus uteri achieved the status of leading gynecologic cancer not only in developed countries, but also in Third World countries. The leading determinants of prognosis and treatment policy are tumor extent and grade at diagnosis. It is important to search for the informative and significant indicators of biological tumor activity, which are determined by pre- and postoperative mini-invasive laboratory studies, the combination of which could additionally judge the extent and grade of a tumor. At present, there are no significant tumor markers for the screening for and evaluation of progressive cancer of the corpus uteri, which would have a high specificity and sensitivity although their search is constantly underway worldwide.
About the Authors
D. B. Olkin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L. I. Bokina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. A. Mustafina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. V. Barinov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
I. I. Bokin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Заридзе Д.Г., Мень Т.Х. Приоритетные направления противораковой борьбы в России. Рос онкол журн 2001;(5):5–14.
2. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225–49.
3. Kanat-Pektas M., Yenicesu O., Gungor T., Bilge U. Predictive power of sexual hormones and tumor markers in endometrial cancer. Arch Gynecol Obstet 2010;281(4):709–15.
4. Takano M., Kikuchi Y., Asakawa T. et al. Identification of potential serum markers for endometrial cancer using protein expression profiling. J Cancer Res Clin Oncol 2010;136(3):475–81.
5. Kuninaka S., Yano T., Yokoyama H. et al. Direct influences of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) on the proliferation and cell-surface antigen expression of cancer cells. Cytokine 2000;12(1):8–12.
6. Cherchi P.L., Dessole S., Ruiu G.A. et al. The value of serum CA 125 and association CA 125/ CA 19-9 in endometrial carcinoma. Eur J Cynaecol Oncol 1999;20(4):315–7.
7. Ginath S., Menczer J., Fintsi Y. et al. Tissue and serum CA125 expression in endometrial cancer. Int. J. Gynecol Cancer 2002;12(4):372–5.
8. Molina R., Auge J.M., Escudero J.M. et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 2010;31(3):171–80.
9. Chung H.H., Kim J.W., Park N.H. et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Chung Acta Obstet Gynecol Scand 2006;85(12):1501–5.
10. Sebastianelli A., Renaud M.C., Gregoire J. et al. Preoperative CA 125 tumor marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can 2010;32(9):856–60.
11. Frumovitz M., Singh D.K., Meyer L. et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 2004;95(3):463–8.
12. Gadducci A., Cosio S., Carpi A. et al. Serum tumour markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;58(1):24–38.
13. Powell J.L., Hill K.A., Shiro B.C. et al. Preoperative serum CA 125 levels in treating endometrial cancer. J Reprod Med 2005;50(8):585–90.
14. Carpenter P.M., Gamboa G.P., Dorion G.E. et al. Radiation-induced CA 125 production by mesothelial cells. Gynecol Oncol 1996;63(3):328–32.
15. Akhmedkhanov A., Zeleniuch-Jacquotte A., Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann NY Acad Sci 2001;943:296–315.
16. Moore R.G., Miller C.M., Brown A.K. et al. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer 2011;21(7):1185–90.
17. Obermair A., Preyer O., Leodolter S. Angiogenesis in gynecology and obstetrics. Wien Klin Wochenschr 1999;111(7):262–77.
18. MacLean A.B., Reid W.M., Rolfe K.J. et al. Role of angiogenesis in benign, premalignant and malignant vulvar lesions. J Reprod Med 2000;45(8):609–12.
19. Dobrzycka B., Terlikowski S.J., Kwiatkowski M. et al. Prognostic significance of VEGF and its receptors in endometrial cancer. Ginekol Pol 2010;81(6):422–5.
20. Linkov F., Gu Y., Arslan A.A. et al. Reliability of tumor markers, chemokines, and metastasis- related molecules in serum. Eur Cytokine Netw 2009;20(1):21–6.
21. West A.F., O'Donnell M., Charlton R.G. et al. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001;85(4):576–83.
22. Price D.J., Miralem T., Jiang S. et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001;12(3):129–35.
23. Nakata B., Hori T., Sunami T. et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 2006;6(3):1175–9.
24. Yoo N.C., Chung H.C., Chung H.C. et al. Synchronous elevation of soluble intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Med J 1998;39(1):27–36.
25. Becker J.C., Termeer C., Schmidt R.E., Bröcker E.B. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 1993;151(12):7224–32.
26. Burger R.A., Darcy K.M., DiSaia P.J. et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer 2004;101(1):106–15.
27. Dotters D.J. Preoperative CA 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 2008;182(6):1328–34.
28. Tabibzadeh S., Satyaswaroop P.G., von Wolff M., Strowitzki T. Regulation of TNF-alpha mRNA expression in endometrial cells by TNF-alpha and by oestrogen withdrawal. Mol Hum Reprod 1999;5(12):1141–9.
29. Balkwill F.R. Inflammation and cancer: the TNF connection. Am Assoc Cancer Res Educ Book 2007. P. 39–42.
30. Grosen E.A., Granger G.A., Gatanaga M. et al. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol Oncol 1993;50(1):68–77.
31. Gadducci A., Ferdeghini M., Fanucchi A. et al. Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in patients with cervical cancer. Oncol Rep 1996;3(5):891–4.
32. Кушлинский Н.Е., Герштейн Е.С., Люби- мова Н.В. Биологические маркеры опухолей: методические аспекты и клиническое приме- нение. Вестн Моск онкол о-ва 2007;(1):6–7.
33. Engelsen I.B., Stefansson I.M., Beroukhim R. et al. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008;32(2):307–16.
34. Кушлинский И.Е. Растворимый фрагмент рецептора HER-2/neu в сыворотке крови больных раком молочной железы с различ- ным уровнем экспрессии этого белка в опу- холи. Клин лаб диагност 2007;(9):18–21.
35. Прохорова В.И. Биологические основы использования растворимого рецептора р185 в прогнозировании результатов лечения па- циенток с метастатическим раком молочной железы. Ars Medica 2010;(1):95–9.
36. Santarosa M., Favaro D., Quaia M. et al. Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int J Cancer 1995;62(3):271–5.
37. Hoopmann M., Sachse K., Valter M.M. et al. Serological and immunohistochemical HER-2/ neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur J Cancer Care 2010;19(6):809–15.
38. Pejic S., Todorovic A., Stojiljkovic V. et al. Antioxidant enzymes and lipid peroxidation in endometrium of patients with polyps, myoma, hyperplasia and adenocarcinoma. Reprod Biol Endocrinol 2009;7:149.
39. Смолякова Р.М. Оценка связывающей способности и транспортной функции сывороточного альбумина у больных раком легкого. Новости хир 2005;13(1–4):78–84.
40. Белоногов Р.Н. Окислительная модификация белков и липидов плазмы крови больных раком легкого. Сиб онкол журн 2009;(4):48–51.
41. Farias-Eisner G., Su F., Robbins T. et al. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol 2010;202(1):73.e1–5.
42. Zhu L.R., Zhang W.Y., Yu L. et al. Serum proteomic features for detection of endometrial cancer. Int J Gynecol Cancer 2006;16(3):1374–8.
Review
For citations:
Olkin D.B., Bokina L.I., Mustafina E.A., Barinov V.V., Bokin I.I. Tumor markers in the diagnosis of cancer of the corpus uteri (a review of literature). Tumors of female reproductive system. 2013;(3-4):67-71. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-3-4-67-71
Views:
672
Email this article 